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Protocol for Biomarker Ratio Imaging
Microscopy with Specific Application
to Ductal Carcinoma In situ of the
Breast
Andrea J. Clark and Howard R. Petty *
Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI, USA
This protocol describes the methods and steps involved in performing biomarker ratio
imaging microscopy (BRIM) using formalin fixed paraffin-embedded (FFPE) samples of
human breast tissue. The technique is based on the acquisition of two fluorescence
images of the same microscopic field using two biomarkers and immunohistochemical
tools. The biomarkers are selected such that one biomarker correlates with breast cancer
aggressiveness while the second biomarker anti-correlates with aggressiveness. When
the former image is divided by the latter image, a computed ratio image is formed
that reflects the aggressiveness of tumor cells while increasing contrast and eliminating
path-length and other artifacts from the image. For example, the aggressiveness of
epithelial cells may be assessed by computing ratio images of N-cadherin and E-cadherin
images or CD44 and CD24 images, which specifically reflect the mesenchymal or
stem cell nature of the constituent cells, respectively. This methodology is illustrated for
tissue samples of ductal carcinoma in situ (DCIS) and invasive breast cancer. This tool
should be useful in tissue studies of experimental cancer as well as the management of
cancer patients.
Keywords: biomarkers, cancer, ductal carcinoma in situ, ratio imaging, microscopy, stem cells, mesenchymal
cells
INTRODUCTION
The advent of novel screening methods have substantially reduced the incidence of advanced
forms of colon and cervical cancers (Janicek and Averette, 2001; Pignone et al., 2002), as might
be expected by removing patients with precursor lesions from the patient pool. Other screening
assays have not had such compelling successes. For example, mammography has had only a minor
effect on the prevalence of invasive breast cancer (Ozanne et al., 2011; Bleyer and Welch, 2012;
Harding et al., 2015). Roughly 64,000 women are diagnosed with ductal carcinoma in situ (DCIS)
(stage 0 cancer) annually in the US. Epidemiological studies suggest that about a quarter of these
patients have indolent disease, which would not affect a patient during her lifetime (Ozanne et al.,
2011; Bleyer and Welch, 2012; Esserman et al., 2013; Marshall, 2014; Harding et al., 2015). Yet all
patients are treated as if they have invasive disease. This response seems reasonable as pathologists
cannot distinguish indolent from aggressive disease, and both the patients and physicians are
gravely concerned about the outcomes. The same concern is found for prostate, lung, thyroid,
and other forms of cancer (Esserman et al., 2014). To better understand cellular aggressiveness
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in biopsy material, we have recently reported biomarker ratio
imaging microscopy (BRIM), which can stratify DCIS tissue
samples using biomarkers related to cancer aggressiveness
and digital image processing. In this protocol article, we
provide background information, rationale, and definitive
methods with step-by-step instructions to examine FFPE samples
using BRIM.
Background: Conventional and
Unconventional Histology
Microscopy has many advantages in studying breast lesions. It
permits the detection of early disease because, in principle, single
dangerous cells can be imaged. In contrast to cell extraction
methods that dilute biomarkers, microscopy allows biomarker
detection within cell organelles at high concentrations. Pathology
labs also employ microscopy, where fixed tissues embedded in
paraffin blocks are standard. Conventional stains, such as
hematoxylin and eosin (H&E), provide the necessary resolution
to distinguish among structural elements of a tissue, which is
exactly what they were intended to do (Figure 1). Biomarkers,
such as the estrogen receptor, progesterone receptor and
HER-2 are used to evaluate breast cancer tissue sections with
immunohistochemistry to provide further information for
patient management (Allred, 2010). For many years, it has
not yet been possible to use molecularly defined biomarkers
to stratify DCIS samples with a sufficient range to provide
prognostic information sufficient to identify aggressive vs.
non-aggressive lesions. We have recently introduced the BRIM
technique, which provides substantially improved stratification
of DCIS lesions by using a combination of biomarkers,
quantitative microscopy and digital image processing (Clark
and Petty, 2016), which should improve our understanding
of tumor cell heterogeneity and contribute to patient
management.
Digital image processing (Figure 1) offers an alternative
approach to conventional optical microscopy; during BRIM,
at least two fluorescence images are collected then processed
by computer. Conventional histology has several drawbacks,
as outlined in Table 1. For quantitative studies, the signal
intensity must be linear with respect to biomarker number.
Hence, enzyme-linked amplification in immunohistochemistry
is inappropriate due to its non-linear characteristics (enzyme
kinetics, inner filter effects, substrate nucleation, etc.) (Exbrayat,
2013). These difficulties are avoided by fluorescence microscopy.
Although fluorescence lamps should always be adjusted for
Köhler illumination, it is possible that spatial variations in
illumination may be found, which distort image brightness in
conventional microscopy. However, ratio imaging microscopy
corrects for spatial artifacts in illumination by comparing
the same pixel at two different wavelengths. One theoretical
limitation of ratio imaging is that the shot noise of a conventional
image is
√
N (N= the number of counts), whereas the shot noise
in a simple ratio image is
√
2N, as expected by the propagation
of error. However, this physical limitation is unimportant in
this application because the increase in percent error introduced
by ratioing at a bin intensity of 104 counts is only 0.4%,
FIGURE 1 | Conventional and unconventional approaches in tissue
evaluation are shown. As illustrated at the top of this figure, tissues may be
stained with dyes to reveal structural features, as illustrated in the H&E stained
tissue sample on the right hand side. This image shows a DCIS lesion
exhibiting the solid architecture. On the lower portion of this figure we illustrate
the digital pathology approach used in the procedures described below. In this
case separate images of CD44 and CD24 immunofluorescence are collected,
then ratioed in silico to reveal a computed image wherein the presence of
CD44hi/CD24lo cells are highlighted. Thus, a subpopulation of tumor cells can
be identified. In this case, an invasive breast disease was studied. Note the
presence of a subset of highly positive CD44hi/CD24lo cells at the periphery of
the duct.
TABLE 1 | Advantages of BRIM Over Conventional Histochemistry.
Numbers Drawbacks of conventional imaging BRIM improvements
1) variations in cell shape ratioing
2) variations in section thickness and loss of
cell material during processing
ratioing
3) non-uniform illumination ratioing
4) enzyme activity and non-linear deposition
of reaction product
fluorescence
5) light absorption by product is non-linear fluorescence
6) modest optical resolution of reaction
products
fluorescence
which is far smaller than the biological variability. Variations in
section thickness, cell shape, and cell size influence a sample’s
perceived brightness (Figure 2), but cancel out in ratio imaging
microscopy (Bright et al., 1989; O’Connor and Silver, 2007; Petty,
2007). In addition, image ratioing has the distinct advantage
of canceling out instrumental factors affecting the brightness of
an image including the numerical aperture (na), magnification
(mag), transmittance of optics (T optics), the detector’s quantum
efficiency (DQE), the detector’s gain (Dgain), the integration
time (t), the fluorophore’s quantum efficiency (F QE), and the
pathlength (pl). As these instrument-specific elements cancel
out, standardization of results among laboratories will be
improved.
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FIGURE 2 | Effect of object shape on perceived brightness by
microscopy. The circle and rectangle have the same volume and particle
number. The circle appears brighter to an observer because it is thicker. The
narrow vertical rectangle represents a vertical volume along the line of sight.
Although the round cell appears “brighter,” the ratio of red to green tags is the
same.
(1)
Image ratioing is best known as a tool to detect calcium signals
(Bright et al., 1989; O’Connor and Silver, 2007; Petty, 2007).
However, it has also be used to detect pH and membrane
potential changes within cells (Bright et al., 1989; O’Connor
and Silver, 2007; Petty, 2007). It is also used, although less
often, in protein activation, polarization, viscosity, proximity,
and water permeability studies (Axelrod, 1989; Nalbant et al.,
2004; Doná et al., 2013). This method has also been used to assess
the interstitial pH of tumors in vivo (Helmlinger et al., 1997).
As described above, two images are collected during ratioing
at two different wavelengths. As the signal of interest, such as
calcium concentration, increases, the image at one wavelength
will increase while the image at a second wavelength will decrease
in brightness. Although the use of one probe emitting at two
wavelengths is frequently used for ratio imaging microscopy, two
fluorescent labels are also used in image ratioing (Floto et al.,
1995; Clark and Petty, 2008; Clark et al., 2010).
Let us next consider a biomarker thought experiment to
illustrate our approach. Previous studies have shown that CD74,
the γ chain of HLA class II antigens, increases during invasive
breast cancer (Porter et al., 2003; Metodieva et al., 2013). On
the other hand, CD59, a complement regulatory protein (Madjd
et al., 2003; Porter et al., 2003), decreases in invasive breast
cancer. Thus, CD74 expression correlates with poor outcomes
while the CD59 level anti-correlates with poor outcomes. As
breast cancer is believed to represent a continuum from normal
to DCIS to invasive and metastatic disease, we quantitatively
compare normal tissue to invasive tissue to estimate the dynamic
range in contrast that might be obtained by ratioing experiments.
Using the gene expression data of Porter et al. (2003), we find
that the average levels of CD74 and CD59 on normal cells were
20 and 41, respectively. In the case of invasive breast cancers, the
levels of CD74 and CD59 were 254 and 5. Thus, the ratio of these
two parameters on normal cells is expected to be 0.49 whereas the
ratio on invasive cells is 50.8. The range of ratios is expected to be
100-fold. As ratioing cancels out path-length and other artifacts,
as well as systematic noise in the tissue section, the large potential
range in contrast with reduced noise and artifacts allow us to
identify CD74hi/CD59lo cells in a subpopulation of DCIS patient
samples (Clark and Petty, 2016).
Biomarker ratio imaging microscopy (BRIM) may be used
to detect well-known cell subpopulations using FFPE samples.
As illustrated on the lower right hand side of Figure 1, BRIM
can identify specific cell subtypes, such as CD44hi/CD24lo
cells. Cells structurally defined as CD44hi/CD24lo cells have
been functionally identified as breast cancer stem cells (Al-Hajj
et al., 2003). Similarly, when cells switch from an epithelial
(N-cadlo/E-cadhi cells) to mesenchymal phenotype (N-cadhi/E-
cadlo cells), the expression of E-cadherin dramatically declines
while the expression of N-cadherin increases. As breast cancer
stem cells have been linked to tumor growth and resistance to
chemotherapy and radiotherapy (Dean et al., 2005; Li et al., 2008),
the presence of CD44hi/CD24lo cells in a tissue sample indicates
tumor aggressiveness. Similarly, the presence of mesenchymal
tumor cells indicates an ability to metastasize (Thiery, 2002;
Ledford, 2011; May et al., 2011), which also indicates aggressive
tumor cells. Thus, multiple breast cancer cell properties may be
assessed using BRIM.
MATERIALS AND EQUIPMENT
Equipment
Biomarker ratio imaging microscopy (BRIM) requires a high-
sensitivity wide-field fluorescence research microscope, such as
the Nikon TE-2000 Quantum, which is used by this laboratory.
To maximize light collection, a high numerical aperture objective
is used. For this application, we typically employ a 20x/0.5
objective to evaluate tissues, which provides good brightness.
Indeed, the mathematic relationship between magnification and
numerical aperture (Equation 1) indicates that this Nikon
objective provides somewhat brighter images than its 40x/0.6
counterpart. In addition to its brightness, this objective is also
a good choice due to: (1) its utility in pathology and (2) at this
magnification many fluorescent labels can be found in each pixel
thus providing a reliable estimate of the ratio. The optical filter
sets require a high % transmittance in the passband, while also
providing the greatest out-of-band reflectance. For ratio imaging,
filter sets with zero pixel shift image registration should be used
(although small registration errors can be corrected in software).
For this application, we recommend the Chroma 49000 ET
series of optical filters (Chroma Technology Corp., Bellows
Falls, VT), which have improved performance characteristics in
comparison to conventional optical filters used in fluorescence
microscopy. The increased transmittance of these filter sets may
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enhance the photobleaching of fluorochromes, but this can be
managed using embedding media that reduce photobleaching
(see below). Specifically, we employ a Chroma 49011 filter set
for Alexa Fluor R© 488 and a Chroma 49004 filter set for Alexa
Fluor R© 568. As the emission spectrum of Alexa Fluor R© 488
overlaps the excitation spectrum of Alexa Fluor R© 568, it is
possible that resonance energy transfer between these two labels
could artifactually lower the apparent level of Alexa Fluor R©
488 emission. This possibility was checked experimentally, and
no significant level of RET was observed between labels. This
result was expected because the biomarkers are not known to
be physically associated with one another. This confirms the
appropriateness of the equipment and labels used in these studies.
It is important to choose a camera with high sensitivity,
low noise, with a linear response to illumination intensity. As
we use a 20x objective, lateral resolution is not important. For
this application, back-illuminated electron-multiplying charge
coupled device (EMCCD) cameras are appropriate. EMCCD
cameras fromAndor Technology (Belfast, UK) and Photometrics
(Tucson, AR) are good choices. These ultra-sensitive cameras
can: detect roughly 1 to 10 photons, operate at low noise (the
EMCCD chips are cooled to −80◦C), and have high quantum
efficiencies with outputs that are linearly proportional with
illumination intensity. As these cameras are built for biological
imaging, their spectral responsivities are nearly 100% in the
green-to-red region of the spectrum, but decrease at higher
and lower wavelengths. The Andor iXon DV887 camera has
16 × 16mm pixels providing a 220,000 pixel well depth. As
ratioing assumes that the images can be quantitatively compared,
it is essential to confirm the linearity of the camera output, as
described in the next section.
Verification of Camera Linearity Using
Bead Intensity Calibration
An InSpeck microscopy image intensity calibration kit
(ThermoFisher Scientific/Molecular Probes) was used to
calibrate the detector. These beads possess different fluorescence
intensities. Beads with 0, 0.4, 1.3, and 4.2% fluorescence were
diluted and imaged with the apparatus described above. Images
of blue fluorescent beads were taken using excitation filter of
350/50 nm, a 415 DRLP dichroic reflector, and a 450DF30 nm
emission filter. Camera settings were identical to those used in all
experiments (see below). It is important to select a range of bead
fluorescence intensities that include the range of fluorescence
intensities to be encountered with biomarker labeling.
After saving the images, they were opened in MetaMorph and
spherical regions of interest were drawn over the beads. Region
measurements were performed to collect average intensity
readings for each type of bead. Measurements were imported
into Microsoft Excel, where the average intensity and standard
deviation were calculated for each bead type. Intensity averages
were plotted vs. the percent of relative intensity given for each
bead type in the kit. The standard deviation for each point was
added as y-error bars, and a linear trend line was calculated.
Figure 3 shows a calibration curve for the camera output, which
was found to be linear.
Supplies
The chemical supplies for BRIM experiments are listed in
Table 2. The antibodies used in these studies are given in Table 3.
Alexa Fluor R© fluorescence labels are used because of their
brightness and photostability. The software programs used in
these studies are Metamorph (v. 7.1.2.0) (Molecular Devices),
Metafluor (v. 7.1.2.0) (Molecular Devices), and ImageJ (NIH).
Biomarkers
Although numerous biomarkers have been identified, they
are not necessarily useful in BRIM studies. The labeling
intensity needs to be appropriate: either rising or falling with
aggressiveness sufficient to provide a high dynamic range after
ratioing. The biomarker distributions within cells are also
important. We have found that ribosomal biomarkers are too
punctate to ratio. We have also found that biomarkers, such
as gene regulatory proteins are not generally useful in BRIM
studies. These biomarkers can translate between the cytoplasm
and the nucleus and cannot be reliably used with current
FIGURE 3 | Calibration of an EMCCD Camera. It is important to calibrate
the camera output to insure that its performance is linear throughout the
brightness region studied in tissue experiments. As described in the text,
individual beads were photographed. The images were then analyzed to
determine the average intensity of each bead preparation. The average bead
intensity is plotted at the ordinate and the percentage of maximal label, as
provided by the manufacturer, is plotted at the abscissa. Note that the output
of the camera is linear with the extent of label.
TABLE 2 | Supplies List for BRIM Protocol.
phosphate buffered saline tablets (Life Technologies; cat# 003002)
Triton X-100 (Sigma; cat# T8787-100 mL)
o-xylene (Sigma; cat# 295884-2 L)
Tween® 20 (Sigma; cat# P7949-100 mL)
citric acid (Sigma; cat# C2404)
sodium citrate dihydrate (Sigma; cat# W302600)
albumin from bovine serum–BSA (Sigma; cat# A7906-50 g)
non-fat dried milk
Prolong Diamond anti-fade mountant (ThermoFisher; cat# P36961)
corning cover glass no. 1 thickness (Corning; 18 × 18mm cat# 2845–18,
25 × 25mm cat# 2865–25, 24 × 50mm cat# 2975–245)
super PAP pen (ThermoFisher; cat# 008899)
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TABLE 3 | Antibody List for BRIM Protocol.
PRIMARY
Antibody Source Cat # Species Ratio
N-Cadherin Abcam ab98952 Ms N-Cad/E-Cad
E-Cadherin Abcam ab15148 Rb N-Cad/E-Cad
CD 74 Abcam ab9514 Ms CD74/CD59
CD 59 Abcam ab133707 Rb CD74/CD59
CD 44 Abcam ab41478 Rb CD44/CD24
CD 24 Biolegend 311102 Ms CD44/CD24
SECONDARY
Antibody Source Cat # Species
Gt anti-Ms Alexa 488 Invitrogen A11029 Gt
Dk anti-Rb Alexa 568 Invitrogen A10042 Dk
software. Thus, the biomarker pairs must be in the same cell
locations for BRIM experiments. We have found that plasma
membranes or mitochondria are particularly useful targets for
BRIM experiments.
Samples
Formalin fixed paraffin-embedded (FFPE) tissue samples were
obtained from National Disease Research Interchange (Bethesda,
MD), the Cooperative Human Tissue Network (Columbus,
OH), and Fox Chase Cancer Center (Philadelphia, PA). These
studies were approved by the University of Michigan’s IRB
with informed consent in accordance with the Declaration of
Helsinki.
STEP-BY-STEP PROCEDURES
Paraffin Removal and Antigen Retrieval
Formalin fixed paraffin-embedded (FFPE) samples are
routinely used by pathology laboratories, and fit within
their normal workflows. We have used BRIM to evaluate
FFPE samples after over 10 years of storage. Others have
reported that these immunochemical procedures can be
successfully employed to study biomarkers on samples
after 30 years of storage (Camp et al., 2000). Hence, BRIM
should be widely useful in the evaluation of pathology
samples.
Paraffin Removal:
1. Obtain paraffin sections from FFPE tissue blocks, and then
mount them on slides.
2. Heat sections to 60◦C in a dry oven for 1 h to soften paraffin.
3. Wash each slide twice in xylene for 5 min to remove paraffin.
Rehydration via ethanol gradient:
4. Wash slides two times for 5 min each in 100% ethanol,
5. Wash for 1 min in each of the following solutions: 95, 80, and
70% of ethanol in water.
6. Wash slides in phosphate buffered saline (PBS) containing
0.02% Triton X-100 two times for 5min each.
Antigen Retrieval:
7. Transfer slides to a slide rack and place in a beaker containing
antigen retrieval buffer (10mM citrate buffer at pH 6.0 with
0.05% Tween R© 20).
8. Place the beaker containing racked slides in a pot of boiling
water, cover with a lid, and steam for 10min.
9. Remove the beaker and allow it to cool to room temperature
for 1 h.
Antibody Labeling of Sections
It is possible that different antibodies directed against the same
biomarker may react with tissue antigens in ways that affect
the ratio observed. This could be due to binding differences,
epitope differences, antigen retrieval differences, or other factors.
Hence, it is crucial to use antibodies specifically reported for this
application (Table 3).
Preparation for Antibody Labeling:
1. Wash slides three times for 15 min each in PBS containing
0.02% Triton X-100.
2. Remove Triton X-100 detergent by washing three times for 15
min each in PBS.
3. Remove slides from wash and dab off excess PBS; circle tissue
using a hydrophobic PAP pen to facilitate labeling.
4. Cover tissue with a solution of 10% non-fat dried milk in
PBS to block non-specific binding and then place onto a
humidified tray for 1 h at room temperature.
Primary Antibody Labeling:
5. After blocking for 1 h, remove the solution and briefly rinse
the slide by dipping into PBS.
6. Cover tissue section with appropriate Ms and Rb primary
antibodies at 2 µg/mL (usually 1:100) in PBS containing 1%
BSA.
7. Gently place slides on a humidified tray that is kept overnight
at 4◦C.
Secondary Antibody Labeling:
8. Wash slides three times for 15 min each in PBS, to remove
unbound primary antibodies.
9. Dab off excess PBS, and cover the tissue section with
secondary antibodies [Alexa Fluor R© 488 goat anti-mouse
(Invitrogen A11029) and Alexa Fluor R© 568 Donkey anti-
rabbit (Invitrogen A10042)] at 20 µg/mL each, in PBS
containing 1% BSA.
10. Place slides on a humidified tray, and move them to the dark
for 1 h, at room temperature.
Mounting Slides:
11. Wash slides three times for 15 min each in PBS, in the dark, to
remove unbound secondary antibodies.
12. Remove slides individually, and dab off excess PBS.
13. Place 1–2 drops (depending on section size) of ProLong R©
Diamond antifade mountant (ThermoFisher Scientific /
Molecular Probes, Eugene, OR) on one end of the section.
14. Place one side of an appropriately-sized coverslip against the
drop(s) of mountant and then slowly and carefully lower the
coverslip using a pipette tip for support to prevent bubbles
from forming.
15. Allow slides to cure at room temperature in the dark for at
least 12 h prior to imaging.
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Microscopy
1. Image slides using a Nikon 20x/0.5 Plan Fluor objective
on a Nikon TE-2000 inverted microscope via an Andor
iXon camera (model DV887ECS-BV) attached to the bottom
port. Plan Fluor or Super Fluor objectives are recommended
due to their chromatic correction, high numerical aperture,
transmittance and flatness across the field.
2. Adjust the Hg lamp for Köhler illumination and then
minimize the iris diameter outside the camera’s field of view.
This procedure reduces the entry of stray fluorescence light
from outside the field of view into the objective.
3. Conduct an initial evaluation of the sample to locate an area
of the section where the numerator biomarker shows bright
staining for imaging.
4. Acquire images via MetaMorph software with the following
settings: exposure time = 100 ms; average = 10 images; EM
gain = 100; CCD temperature = −80◦C; 14-bit digitizer;
vertical shift speed = 294.12 kHz; vertical clock voltage =
normal; pre-amplifier gain = 1.00 x; camera state = non-
overlapped; binning= 1.
5. Take a white light image of the field without EM gain for
reference.
6. Collect a green fluorescence image using a Chroma 49011
filter set comprised of a 480/40 nm excitation filter, a 510 nm
dichroic reflector, and a 535/50 nm emission filter.
7. Switch the filter cube to a Chroma 49004 filter set comprised
of a 545/25 nm excitation filter, a 535 nm dichroic reflector,
and a 605/70 nm emission filter to collect an image of
red fluorescence. Both images are collected of the same
microscopic field at the same focal plane.
8. Save and then close images.
Image Processing
1. Reopen biomarker image pairs (Alexa Fluor R© 488 and 568) of
the same field in MetaMorph software.
2. Use the “add plane” function to create a two image stack: the
image corresponding to the numerator should be on top of the
stack whereas the image corresponding to the denominator
should be on the bottom of the stack.
3. Save and then close the image stack.
4. Open MetaFluor software, and select the “build INF file”
option under the utilities tab.
5. Select each image stack from the previous step and make
an.INF file using the following options: Image type–Stack file;
number of wavelengths–2; equally space images by 102 ms
(image spacing is unnecessary); the files can now be opened
by MetaFluor.
6. Open the.INF files in the MetaFluor workspace, which will
result in a ratio image. Select “display” to allow the image
parameters to be set, including the range of the calculated
ratio image displayed (in this case 0–4). An exclusive threshold
should be set on each of the original images to eliminate areas
of the image that are “holes” in the section itself (no cells or
tissue).
7. Select the “Save ratios” option to name the ratio image file. File
name includes sample identification code, the field number,
ratio range, and the antigens used in the ratio. Press the play
button to save the image.
Image Analysis: Quantification of Image
Data
Although images can be judged as high or low BRIM tissue
samples by simple visual inspection, it is necessary to quantify
image properties for statistical analysis.
1. Use ImageJ software to further process the raw ratio tiff files.
After opening, confirm that the Image Type on the pull-down
menu is 8-bit.
2. On the Image-Adjust-Threshold pop-up window, adjust the
count area to 130–255. As previously described (Clark and
Petty, 2016), this range of values was selected because it
corresponded to ratios uniquely associated with aggressive
disease. Investigators may need to assess the proper lower
bound for their particular experimental set-up to avoid
overlap with normal breast tissue or fibroadenoma tissue
(Clark and Petty, 2016). This threshold removes essentially
all of the low ratios associated with normal tissue; if
the red button is pressed, the ratios associated with
aggressive biomarker ratios will be highlighted red in the
image.
3. Under the Analyze menu, depressing the Analyze Particles
command of the pull-down bar will cause the analyze particles
pop-up window to be shown. Type in 5 for the minimum
size of the particles in pixels. Smaller particle sizes may
have a tendency to pick up noise in the ratio image. This
step produces several image metrics, such as count and area.
Parameters, such as particle count can be used to compare
patient samples.
RESULTS AND DISCUSSION
Suppression of Systematic Noise and
Pathlength Differences
We have previously mentioned some of the advantages of
ratio imaging microscopy in the analysis of tissue sections
(Table 1, Equation 1). Systematic noise is a common element in
conventional histology. For example, in our recent paper (Clark
and Petty, 2016), we illustrated the suppression of systematic
noise during BRIM. Irregularities in sections, such as knife
chatter, is suppressed because it is present in both the numerator
and denominator images, and hence, cancels out when the ratio
is computed. Similar types of systematic noise, such as scratches
due to machining of slide or cover-slip surfaces or patterns
formed when nylon or formvar matrices are used as support
structures should be minimized. Although the non-specific
binding of antibodies can be managed by blocking reagents, it is
not perfect. The non-specific staining of tissues with fluorescent
second-step antibodies is a potential source of systematic noise.
When this idea was tested in a BRIM experiment (with the
brightness increased to make the non-specific fluorescence easier
to visualize), we found that the non-specific component of
sample fluorescence was dramatically reduced (data not shown).
In Figure 4, we show a mesh support with non-specifically
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bound Alexa Fluor R© 488-labeled antibodies and Alexa Fluor R©
568-labeled antibodies. Areas of mesh overlap are brighter
because they are thicker than regions of single strands. However,
after ratioing, the non-specific staining of the mesh disappears
because it is ratioed to one (Figure 4D); this also illustrated that
the pathlength artifacts of overlapping strands also disappear.
This approach may be useful in the analysis of tissues with high
levels of autofluorescence. For example, lipofusin in tissues, such
as the retina is highly fluorescent across the visible spectrum, and
could be managed with this approach. Thus, the methodology
described above might be applicable in many areas of
pathology.
Illustration of BRIM
Figure 5 shows an example of a BRIM experiment. These
micrographs show CD74 and CD59 experiments (examples of
N-cadherin, E-cadherin, CD44 and CD24 experiments are shown
below in Figure 6). Figure 5A shows an H and E image of a
serial section of this region of the sample. CD74 (numerator) and
CD59 (denominator) are shown in Figures 5B,C, respectively.
A pseudocolor ratio image is shown in Figure 5D. In these
three micrographs, a CD74lo/CD59hi cell and a CD74hi/CD59lo
cell are illustrated as cell 1 and 2, respectively. Thus, when
CD74 is high and CD59 is low, very large ratios are observed.
Alternatively, when CD74 is low and CD59 is high, very
low ratios are found. As Figure 5D shows, a wide range of
ratios are obtained. Importantly, many CD74hi/CD59lo cells are
found, which suggests that the lesion contains aggressive cells,
as CD74 correlates with adverse patient outcomes and CD59
correlates with positive patient outcomes (or inversely correlates
with aggressiveness) (Madjd et al., 2003; Porter et al., 2003;
Metodieva et al., 2013). The high number of CD74hi/CD59lo
cells is consistent with the diagnosis of invasive breast
cancer.
FIGURE 4 | Example of Ratio Imaging Microscopy. A nylon mesh was non-specifically coated with Alexa Fluor® 488-labeled antibodies and Alexa Fluor®
568-labeled antibodies then air-dried. (A) shows the meshwork using bright-field microscopy; the overlapping regions should be noted. (B,C) show the green and red
fluorescence emission channels, respectively. The ratio image of Alexa Fluor® 488 emission divided by Alexa Fluor® 568 emission was calculated, which is shown in
(D). It should be noted that the pathlength differences in areas of mesh overlap disappear and that the non-specific staining in (B,C) disappear by ratioing to one.
(Ratio scale bars are given along the right hand side of each panel.) (5x objective).
FIGURE 5 | Tissue Illustration of BRIM. This figure shows images of: (A) H and E image, (B) CD74 (numerator), (C) CD59 (denominator), and (D) CD74/CD59
(ratio). The micrograph in (A) was obtained using H&F staining followed by imaging with a color camera. This tissue sample was derived from a patient diagnosed with
invasive breast cancer. As H&F staining should not be performed on the same slide as immunofluorescence imaging, the micrographs of (A–C) were taken from serial
sections. Hence, (A) is similar to, but not identical with, (B–D). The images of (B,C) were autoscaled for clarity of illustration, but not in the calculation of the ratio in
(D). This image was chosen for pedagogical purposes because it illustrates the principles of BRIM. Due to the brightness in each channel, cell subtypes are easily
discerned. (B) shows the numerator, CD74. Two cells are designated as 1 and 2. Cell 1 is a CD74lo/CD59hi cell whereas Cell 2 is a CD74hi/CD59lo cell. This
illustrates the fact that different cell populations are present. As the differences in CD74 and CD59 levels are very large, a considerable improvement in gain can be
observed. As anticipated by genomic studies (Porter et al., 2003), large differences in CD74 and CD59 levels can be observed in invasive breast cancer cells, as
physically manifested in the BRIM micrograph of (D). In the case of DCIS, a large range of ratios is observed (Clark and Petty, 2016). (D) shows a field containing
many CD74hi/CD59lo cells. Such high numbers of CD74hi/CD59lo cells are not found in normal breast tissue, fibroadenoma of the breast, and a sub-population of
DCIS samples (Clark and Petty, 2016). A ratio scale bar is given along the right hand side of (D) (20x objective).
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FIGURE 6 | Pseudocolor BRIM images of CD44hi/CD24lo cells and
N-cadhi/E-cadlo cells of DCIS lesions are shown. (A,C) show
CD44hi/CD24lo cells whereas (B,D) show N-cadhi/E-cadlo cells. Positive
BRIM findings (high ratios) are shown in (A,B). Negative BRIM results (low
ratios) are shown in (C,D). Higher ratios are indicated by the red-yellow colors
in (A,B). Arrows denote regions of higher ratios. Note that the CD44hi/CD24lo
cells are primarily found at the periphery of the ducts in (A). These data show
that patients can differ widely in the ratios associated with DCIS. (Ratio scale
bars are given along the right hand side of each panel) (20x objective).
Characterization of Cell Types in DCIS
We will now illustrate the results obtained when BRIM is used
to study DCIS lesions. Figure 6 shows BRIM micrographs of
DCIS lesions stained for CD44hi/CD24lo cells and N-cadhi/E-
cadlo cells. Figure 6A shows that CD44hi/CD24lo cells, which are
a key feature of breast cancer stem cells (Al-Hajj et al., 2003), may
be found in DCIS ducts, especially at the perimeter. However,
DCIS lesions of other patients can be negative, as illustrated
in Figure 6C. Similarly, Figures 6B,D show N-cadhi/E-cadlo
cells, which illustrate the mesenchymalness of the cells, a trait
associated with the ability of cells to metastasize (Li et al., 2008).
Positive cells are shown in panel B, whereas negative cells are
shown in panel D. Distributions of BRIM scores of a DCIS patient
population for stemness and mesenchymalness is shown in our
previous study (Clark and Petty, 2016). Thus, the suppression of
noise and the enhancement of BRIM offer significant advantages
in the identification of aggressive and non-aggressive cells in
DCIS lesions.
Conclusions and Future Applications
In this protocol article we have described, in substantial detail,
BRIM, a new and unconventional approach in the study of
tissue samples that provides unprecedented insight into the
aggressiveness of cancerous lesions. To quickly implement these
protocols, we recommend collaborations between biophysicists
with experience in ratio imaging microscopy, such as the ratio
imaging of calcium concentrations, and scientists or physicians
interested in immunohistology.
We anticipate that this approach will impact both basic
cancer research and in the clinical assessment of biopsies. The
many advantages of BRIM could also be extended to other
areas of cancer research, such as other types of over-diagnosed
cancers (Esserman et al., 2014). As breast cancer stem cells are
resistant to chemotherapy and radiotherapy (Dean et al., 2005;
Li et al., 2008), the extent of CD44hi/CD24lo cells in biopsies
may provide information regarding potential level resistance
to therapy, and thereby help to guide treatment. BRIM will
also find many applications in drug development because of
its lower cost than other methods for assessing the phenotypic
properties of tumor cells. For example, one could ascertain
the phenotype of tumor cells within animal samples after
treatment with emerging anti-stem cell or anti-mesenchymal cell
pharmaceuticals. In addition, other types of biomarkers could
be employed. For example, BRIM could be used to monitor the
percentage of a phosphorylated oncogene vs. the total oncogene
pool, wherein the anti-oncogene antibody is a “standard candle”
to assess relative changes in phosphorylation. This could also
be employed more broadly to investigate signal transduction
in tissues. Differences in the locations of signal transduction
events within tissues and within single cells could be visualized.
Hence, we feel that BRIM will be broadly used in the analysis of
tissue properties, and that many additional applications will be
found.
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